Zevra Therapeutics, Inc. (ZVRA)
| Market Cap | 696.38M +78.0% |
| Revenue (ttm) | 122.29M +201.3% |
| Net Income | 117.00M |
| EPS | 1.98 |
| Shares Out | 59.12M |
| PE Ratio | 5.94 |
| Forward PE | 18.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,454,442 |
| Open | 11.25 |
| Previous Close | 11.12 |
| Day's Range | 11.20 - 12.06 |
| 52-Week Range | 7.16 - 13.16 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 23.33 (+98.05%) |
| Earnings Date | May 6, 2026 |
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $23.33, which is an increase of 98.05% from the latest price.
News
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseas...
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim
Guggenheim analyst Eddie Hickman raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the shares. The firm expects growth to…
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c
Reports Q1 revenue $36.2M, consensus $31.96M. In Q1, the company received $40.5M of the $45M in net proceeds from the sale of the SDX portfolio. “Our results demonstrate the differentiated…
Zevra Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 78% revenue growth, strong net income, and debt-free status driven by MIPLYFFA's U.S. launch and global expansion, SDX asset sale, and robust pipeline progress. MIPLYFFA now reaches about half of diagnosed U.S. NPC patients, with continued growth expected.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 mil...
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare dise...
Zevra Therapeutics sells SDX portfolio to Commave for $50M
Zevra Therapeutics (ZVRA) announced an agreement under which Commave Therapeutics will purchase Zevra’s serdexmethylphenidate portfolio, including AZSTARYS and KP1077, for $50 million. Zevra and Comma...
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare dise...
Zevra Therapeutics initiated with a Buy at BTIG
BTIG analyst Kambiz Yazdi initiated coverage of Zevra Therapeutics (ZVRA) with a Buy rating and $23 price target Zevra’s current valuation appears to reflect conservative adoption of Miplyffa limited ...
Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Strong commercial growth and rapid market penetration for MIPLYFFA, with robust diagnosis and persistency rates, are driving expansion in the U.S. and Europe. Strategic investments and disciplined capital allocation support ongoing pipeline development and global access initiatives.
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $22 and keeps a Buy rating on the shares. Miplyffa’s launch continues to perform well, with FY25…
Zevra Therapeutics Earnings Call Transcript: Q4 2025
Net revenue reached $106.5 million in 2025, driven by MIPLYFFA's strong U.S. and global performance, with 52 annual enrollments and expanding access. Net income swung to $83.2 million, and the company remains well-capitalized for continued growth and pipeline advancement.
Zevra Therapeutics reports Q4 EPS 20c, consensus 5c
Reports Q4 revenue $34.1M, consensus $28.05M. “Miplyffa is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confide...
Zevra Therapeutics Inc options imply 4.6% move in share price post-earnings
Pre-earnings options volume in Zevra Therapeutics (ZVRA) Inc is 1.2x normal with calls leading puts 8:1. Implied volatility suggests the market is anticipating a move near 4.6%, or 41c, after…
Options Volatility and Implied Earnings Moves Today, March 09, 2026
Today, several major companies are expected to report earnings: 3D Systems (DDD), Casey’s General (CASY), Coherus Biosciences (CHRS), Fuelcell Energy (FCEL), W&T Offshore (WTI), Zevra Therapeutics (ZV...
Zevra Therapeutics appoints Renz as Chief Financial Officer
Zevra Therapeutics (ZVRA) announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz most recently served as Chief Financial & Operations Officer at Ardelyx (AR...
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wit...
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseas...
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigatio...
Zevra Therapeutics presents real-world data on Miplyffa
Zevra Therapeutics (ZVRA) announced the presentation of four posters highlighting positive new data on Miplyffa for the treatment of Niemann-Pick Disease Type C at the 22nd Annual WORLDSymposium. “The...
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients Real-world and clinical trial data underscore long-term safety and effectiveness in...
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD
Zevra Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong financials and disciplined strategy support rapid growth in rare disease therapeutics, with Miplyffa achieving significant U.S. market penetration and global expansion underway. Key catalysts include EMA review, patent extension, and innovative patient identification initiatives.